The price-to-earnings ratio for Organon & Co (NYSE: OGN) is above average at 4.69x, Company’s 36-month beta value is 0.67.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for OGN is 257.25M, and currently, short sellers hold a 6.93% ratio of that floaft. The average trading volume of OGN on March 18, 2025 was 3.54M shares.
OGN) stock’s latest price update
The stock price of Organon & Co (NYSE: OGN) has jumped by 2.02 compared to previous close of 15.31. Despite this, the company has seen a fall of -0.70% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-17 that In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon’s dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
OGN’s Market Performance
Organon & Co (OGN) has experienced a -0.70% fall in stock performance for the past week, with a -4.29% drop in the past month, and a -0.38% drop in the past quarter. The volatility ratio for the week is 3.43%, and the volatility levels for the past 30 days are at 4.03% for OGN.. The simple moving average for the past 20 days is 2.70% for OGN’s stock, with a -13.15% simple moving average for the past 200 days.
Analysts’ Opinion of OGN
Many brokerage firms have already submitted their reports for OGN stocks, with JP Morgan repeating the rating for OGN by listing it as a “Underweight.” The predicted price for OGN in the upcoming period, according to JP Morgan is $20 based on the research report published on September 06, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see OGN reach a price target of $16, previously predicting the price at $33. The rating they have provided for OGN stocks is “Neutral” according to the report published on November 03rd, 2023.
Barclays gave a rating of “Overweight” to OGN, setting the target price at $28 in the report published on September 21st of the previous year.
OGN Trading at 1.23% from the 50-Day Moving Average
After a stumble in the market that brought OGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.38% of loss for the given period.
Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 3.43%, as shares surge +2.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.69% upper at present.
During the last 5 trading sessions, OGN fell by -0.70%, which changed the moving average for the period of 200-days by -25.55% in comparison to the 20-day moving average, which settled at $15.21. In addition, Organon & Co saw 4.69% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for OGN
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.58 for the gross margin
The net margin for Organon & Co stands at 0.13. The total capital return value is set at 0.11. Equity return is now at value 429.85, with 6.87 for asset returns.
Based on Organon & Co (OGN), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 18.81. The interest coverage ratio of the stock is 2.29.
Currently, EBITDA for the company is 1.6 billion with net debt to EBITDA at 4.97. When we switch over and look at the enterprise to sales, we see a ratio of 1.91. The receivables turnover for the company is 4.72for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
In a nutshell, Organon & Co (OGN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
